Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital health, is pleased to announce new
collaborative alliances with Dr. Pierce Nunley and the Spine
Institute of Louisiana, a prestigious medical facility and one of
the top 20 patient-rated U.S. hospitals for best overall care, and
Dr. Alexander Vaccaro, an advisor to Surgalign and one of the
top-ranked spine experts in the world.
These new collaborations seek to advance Surgalign’s recently
introduced HOLO™ AI Insights solution for lumbar spine imaging,
which was launched in March 2023, and build upon the previous
collaboration with Spine Institute of San Diego. All of the parties
involved are focused on using HOLO AI Insights with a goal to
enhance clinical decision support and patient care through the use
of artificial intelligence (AI).
HOLO AI Insights enables customers, partners, and clinical
researchers to take advantage of the Company’s AI portfolio through
a secure, highly scalable cloud platform for automated analysis of
medical images. HOLO AI Insights analyzes standard protocol lumbar
spine MRI images, providing quantitative measurements of 16
different anatomic structures in the spine, which in turn, are used
to turn imaging data into structured datasets of clinically
relevant biomarkers in patient populations. While the current
solution is for research use and addresses the spine, the Company
believes its AI portfolio and the insights generated have the
potential for multiple applications in population health, clinical
research and overall patient care.
Dr. Vaccaro has served as President of Rothman Orthopaedics
since 2014 and is the Richard H. Rothman Professor and Chairman in
the Department of Neurosurgery at Thomas Jefferson University in
Philadelphia, PA. He was the recipient of the Lon Wiltse award
given for excellence in leadership and clinical research for spine
care by the North American Spine Society (NASS) and is the past
President of Cervical Spine Research Society (CSRS), the American
Spinal Injury Association and the Association for Collaborative
Spine Research. He has over 900 peer-reviewed and 200 non-peer
reviewed publications and is widely regarded as one of the top
spine surgeons in the world. In 2021, he was named the #1 spine
expert in the world by Expertscape, which examined medical
publications indexed in the National Library of Medicine’s Medline
database.
Dr. Vaccaro commented, “I’ve had the privilege of working with
many companies in evaluating and developing new technologies.
Surgalign, in my opinion, is one of the most exciting given the
groundbreaking work they are doing with artificial intelligence.
With HOLO AI Insights, for the first time, we will be able to
assess imaging with real, quantitative information which should
drive more informed clinical decisions and ultimately, help drive
better patient outcomes.”
Dr. Nunley, who will be leading efforts for Spine Institute of
Louisiana, is an experienced clinical research Principal
Investigator for over 20 years. He is the founder and Medical
Director of the Spine Institute of Louisiana and an Associate
Professor in the Department of Orthopedic Surgery at LSU Health
Sciences Center, where he has served as a clinical instructor since
1999. He is co-founder of The Spine Network (TSN), an organization
dedicated to excellence and pioneering and integrating disruptive
technologies, including AI, in Spine Research. He is a member of
many professional institutions including, the International Spine
Study Group (ISSG), Cervical Spine Research Society (CSRS),
Scoliosis Research Society (SRS), Society for Minimally Invasive
Spine Surgery (SMISS), North American Spine Society (NASS),
American Academy of Orthopaedic Surgeons (AAOS), and the
International Society for the Advancement of Spine Surgery
(ISASS).
Dr. Nunley commented, “Our team is dedicated to the treatment of
spinal disorders by using accurate and thorough diagnostic tools,
advanced technologies and best practices, both in surgical
procedures and treatment plans. Through HOLO AI Insights, we gain a
clearer picture of medical images based on quantifiable data which
can assist us in formulating clinical guidance for our patients. AI
is becoming more prominent in the medical field and we look forward
to working with Surgalign to unlock its potential.”
Terry Rich, President and Chief Executive Officer of Surgalign
added, “Gaining surgeon feedback is paramount to the continuous
advancement of our AI technology and with Dr. Vaccaro, Dr. Nunley,
and the team at San Diego Spine Foundation, we have aligned with
some of the best spine surgeons in the world. We look forward to
working with them to gain their insights and enhance our AI
capabilities to drive further adoption in the market and improve
patient care.”
About Surgalign Holdings, Inc.Surgalign
Holdings, Inc. is a global medical technology company committed to
the promise of digital health to drive transformation across the
surgical landscape. Uniquely aligned and resourced to advance the
standard of care, the company is building technologies physicians
and other health providers will look to for what is truly possible
for their patients. Surgalign is focused on developing solutions
that predictably deliver superior clinical and economic outcomes.
Surgalign markets products throughout the United States and in
approximately 50 countries worldwide through an expanding network
of top independent distributors. Surgalign is headquartered in
Deerfield, IL, with commercial, innovation and design centers in
San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany.
Learn more at www.surgalign.com and connect on LinkedIn and
Twitter.
Forward Looking StatementThis press release
contains forward-looking statements based on management’s current
expectations, estimates and projections about our industry, our
management’s beliefs and certain assumptions made by our
management, and such forward-looking statements include (among
others) statements regarding anticipated future financial and
operating performance (including forecasted full-year revenue and
number of HOLO sites secured), product rationalization and expense
reduction initiatives and the results thereof, potential third
party financing and anticipated cash needs. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” variations of such words and similar expressions are
intended to identify such forward-looking statements. The
forward-looking statements are not guarantees of future performance
and are based on certain assumptions including general economic
conditions, as well as those within the Company’s industry, and
numerous other factors and risks identified in the Company’s most
recent Form 10-K, 10-Q and other filings with the SEC. Our actual
results may differ materially from the anticipated results
reflected in these forward-looking statements. Important factors
that could cause actual results to differ materially from the
anticipated results reflected in these forward-looking statements
include risks and uncertainties relating to the following: (i) the
Company’s access to adequate operating cash flow, trade credit,
borrowed funds and equity capital to fund its operations and pay
its obligations as they become due, and the terms on which external
financing may be available, including the impact of adverse trends
or disruption in the global credit and equity markets; (ii) risks
relating to existing or potential litigation or regulatory actions;
(iii) the identification of control deficiencies, including
material weaknesses in internal control over financial reporting;
(iv) general worldwide economic conditions and related
uncertainties; (v) the continued impact of the COVID-19 and the
Company’s attempts at mitigation, particularly in international
markets served by the Company; (vi) the failure by the Company to
identify, develop and successfully implement its strategic
initiatives, particularly with respect to its digital surgery
strategy; (vii) the reliability of our supply chain; (viii) our
ability to meet obligations, including purchase minimums, under our
vendor and other agreements; (ix) whether or when the demand for
procedures involving our products will increase; (x) our financial
position and results, total revenue, product revenue, gross margin,
and operations; (xi) failure to realize, or unexpected costs in
seeking to realize, the expected benefits of the Holo Surgical Inc.
(“Holo Surgical”) and Inteneural Networks Inc. (“INN”)
acquisitions, including the failure of Holo Surgical’s and INN’s
products and services to be satisfactorily developed or achieve
applicable regulatory approvals or as a result of the failure to
commercialize and distribute its products; (xii) the failure to
effectively integrate Holo Surgical’s and INN’s operations with
those of the Company, including: retention of key personnel; the
effect on relationships with customers, suppliers, and other third
parties; and the diversion of management time and attention to the
integration; (xiii) the number of shares and amount of cash that
will be required in connection with any post-closing milestone
payments, including as a result of changes in the trading price of
the Company’s common stock and their effect on the amount of cash
needed by the Company to fund any post-closing milestone payments
in connection with the acquisitions; (xiv) the continuation of
recent quality issues with respect to our global supply chain; (xv)
the effect and timing of changes in laws or in governmental
regulations; and (xvi) other risks described in our public filings
with the SEC. These factors should be considered carefully, and
undue reliance should not be placed on the forward-looking
statements. Each forward-looking statement in this communication
speaks only as of the date of the particular statement. Copies of
the Company's SEC filings may be obtained by contacting the Company
or the SEC or by visiting Surgalign’s website at
http://www.surgalign.com/ or the SEC’s website at
http://www.sec.gov/. We undertake no obligation to update these
forward-looking statements except as may be required by law.
Investor and Media Relations Contact:Glenn
WienerGwiener@gwcco.com+1 917 887 8434
Surgalign (NASDAQ:SRGA)
過去 株価チャート
から 4 2024 まで 5 2024
Surgalign (NASDAQ:SRGA)
過去 株価チャート
から 5 2023 まで 5 2024